This was similarly found for the subsample of this study reported in Brandi et al. (2020), with a 7.90 % decrease in oxytocin concentrations in patients with craniopharyngioma, compared to a 21.26 % increase in controls. This evidence concerns the gene OXT and craniopharyngioma.